HUP0203914A2 - High order nucleic acid based structures - Google Patents

High order nucleic acid based structures

Info

Publication number
HUP0203914A2
HUP0203914A2 HU0203914A HUP0203914A HUP0203914A2 HU P0203914 A2 HUP0203914 A2 HU P0203914A2 HU 0203914 A HU0203914 A HU 0203914A HU P0203914 A HUP0203914 A HU P0203914A HU P0203914 A2 HUP0203914 A2 HU P0203914A2
Authority
HU
Hungary
Prior art keywords
nucleic acid
high order
acid based
subject
based structures
Prior art date
Application number
HU0203914A
Other languages
Hungarian (hu)
Inventor
Frank J Carr
Graham Carter
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9926810.4A external-priority patent/GB9926810D0/en
Priority claimed from GB0011126A external-priority patent/GB0011126D0/en
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HUP0203914A2 publication Critical patent/HUP0203914A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C12N2310/151—Nucleic acids forming more than 2 strands, e.g. TFOs more than 3 strands, e.g. tetrads, H-DNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/52—Physical structure branched

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A találmány tárgyát nukleinsavalapú molekuláris struktúrák képezik,amelyek más típusú molekulákhoz, különösen maguktól a nukleinsavaktóleltérő molekuláris entitásokhoz képesek kötődni. A találmány tárgyátközelebbről gyógyászati aktivitással rendelkező, nukleinsavalapúmolekuláris struktúrák képezik, amelyek aktivitásukat specifikusmolekuláris célpontokhoz való kötődés útján fejtik ki, ezáltalbetegségekkel kapcsolatos állapotokra vannak hatással. Szintén atalálmány tárgyát képezi a találmány szerinti nukleinsavalapúmolekuláris struktúrák diagnosztikai alkalmazása. ÓThe subject of the invention is nucleic acid-based molecular structures capable of binding to other types of molecules, especially to molecular entities different from nucleic acids themselves. More specifically, the subject of the invention is nucleic acid-based molecular structures with therapeutic activity, which exert their activity by binding to specific molecular targets, thereby affecting disease-related conditions. Also the subject of the invention is the diagnostic application of the nucleic acid-based molecular structures according to the invention. HE

HU0203914A 1999-11-13 2000-11-13 High order nucleic acid based structures HUP0203914A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9926810.4A GB9926810D0 (en) 1999-11-13 1999-11-13 High order nucleic acid-based structures
GB0011126A GB0011126D0 (en) 2000-05-10 2000-05-10 High order nucleic acid-based structures
PCT/EP2000/011197 WO2001036624A1 (en) 1999-11-13 2000-11-13 High order nucleic acid based structures

Publications (1)

Publication Number Publication Date
HUP0203914A2 true HUP0203914A2 (en) 2003-03-28

Family

ID=26244234

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203914A HUP0203914A2 (en) 1999-11-13 2000-11-13 High order nucleic acid based structures

Country Status (16)

Country Link
EP (1) EP1228201A1 (en)
JP (1) JP2003522524A (en)
KR (1) KR20020059727A (en)
CN (1) CN1390253A (en)
AU (1) AU782880B2 (en)
BR (1) BR0015484A (en)
CA (1) CA2391084A1 (en)
CZ (1) CZ20021472A3 (en)
HK (1) HK1052529A1 (en)
HU (1) HUP0203914A2 (en)
MX (1) MXPA02004727A (en)
NO (1) NO20022231L (en)
PL (1) PL358811A1 (en)
RU (1) RU2002113755A (en)
SK (1) SK6042002A3 (en)
WO (1) WO2001036624A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2358385C (en) 1998-12-31 2013-08-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP2412242A3 (en) 2001-07-05 2012-06-13 Novartis Vaccines and Diagnostics, Inc. Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
CA2849072A1 (en) 2011-08-05 2013-02-14 President And Fellows Of Harvard College Compositions and methods relating to nucleic acid nano-and micro-technology
WO2014018675A1 (en) 2012-07-24 2014-01-30 President And Fellows Of Harvard College Self-assembly of nucleic acid nanostructures
US9975916B2 (en) 2012-11-06 2018-05-22 President And Fellows Of Harvard College Compositions and methods relating to complex nucleic acid nanostructures
US20160271268A1 (en) * 2013-11-08 2016-09-22 Dana-Farber Cancer Institute, Inc. Nucleic acid nanostructures for in vivo agent delivery
US10099920B2 (en) 2014-05-22 2018-10-16 President And Fellows Of Harvard College Scalable nucleic acid-based nanofabrication
US11414694B2 (en) 2016-03-11 2022-08-16 Children's Medical Center Corporation Nucleic acid nanoswitch catenanes
WO2018026880A2 (en) 2016-08-02 2018-02-08 President And Fellows Of Harvard College Crisscross cooperative self-assembly
CN110711254B (en) * 2018-07-12 2022-07-26 百药智达（北京）纳米生物技术有限公司 Nucleic acid nanoparticles and pharmaceutical compositions comprising the same
JP7267416B2 (en) * 2018-07-12 2023-05-01 百薬智達（北京）納米生物技術有限公司 Nucleic acid nanoparticles, pharmaceutical composition containing same, drug containing adriamycin and method for producing same
CN110960534B (en) * 2018-09-30 2022-07-26 百药智达（北京）纳米生物技术有限公司 Medicine containing pentafluorouracil, preparation method thereof, pharmaceutical composition and application thereof
CN110960536B (en) * 2018-09-30 2022-07-26 百药智达（北京）纳米生物技术有限公司 Aspirin-containing medicine, preparation method, pharmaceutical composition and application thereof
CN110960690B (en) * 2018-09-30 2022-07-22 百药智达（北京）纳米生物技术有限公司 Medicine containing epirubicin, preparation method thereof, pharmaceutical composition and application thereof
CN110960542B (en) * 2018-09-30 2022-07-26 百药智达（北京）纳米生物技术有限公司 Medicament containing pirarubicin, preparation method thereof, pharmaceutical composition and application thereof
CN110960530B (en) * 2018-09-30 2022-07-22 百药智达（北京）纳米生物技术有限公司 Tacrine-containing medicine, preparation method thereof, pharmaceutical composition and application thereof
CN111053765B (en) * 2018-10-16 2022-07-26 百药智达（北京）纳米生物技术有限公司 Medicine containing paclitaxel, preparation method, pharmaceutical composition and application thereof
CN111068065B (en) * 2018-10-22 2022-07-26 百药智达（北京）纳米生物技术有限公司 Drug containing oxaliplatin, preparation method thereof, pharmaceutical composition and application thereof
CN111084887B (en) * 2018-10-23 2022-07-22 百药智达（北京）纳米生物技术有限公司 Flavone-containing medicine, preparation method thereof, medicine composition and application
CN111096965B (en) * 2018-10-29 2022-07-26 百药智达（北京）纳米生物技术有限公司 Medicine containing dihydroartemisinin, preparation method thereof, medicine composition and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985000813A1 (en) * 1983-08-03 1985-02-28 The Research Foundation Of State University Of New Nucleic acid branched junctions with precisely defined migrational mobility
US5386020A (en) * 1991-01-10 1995-01-31 New York University Multiply connected, three-dimensional nucleic acid structures
US5278051A (en) * 1991-12-12 1994-01-11 New York University Construction of geometrical objects from polynucleotides
US6072044A (en) * 1996-04-26 2000-06-06 New York University Nanoconstructions of geometrical objects and lattices from antiparallel nucleic acid double crossover molecules

Also Published As

Publication number Publication date
KR20020059727A (en) 2002-07-13
PL358811A1 (en) 2004-08-23
CN1390253A (en) 2003-01-08
NO20022231D0 (en) 2002-05-10
BR0015484A (en) 2002-07-02
AU782880B2 (en) 2005-09-08
CZ20021472A3 (en) 2002-07-17
EP1228201A1 (en) 2002-08-07
AU2000101A (en) 2001-05-30
RU2002113755A (en) 2004-01-10
JP2003522524A (en) 2003-07-29
WO2001036624A1 (en) 2001-05-25
SK6042002A3 (en) 2002-12-03
HK1052529A1 (en) 2003-09-19
NO20022231L (en) 2002-05-10
MXPA02004727A (en) 2002-08-30
CA2391084A1 (en) 2001-05-25

Similar Documents

Publication Publication Date Title
HUP0203914A2 (en) High order nucleic acid based structures
RS51847B (en) Binding molecules capable of neutralizing rabies virus and uses thereof
BR0009762A (en) Catalyst for production of acetic acid or acetic acid and ethyl acetate, process for its production and process for production of acetic acid or acetic acid and ethyl acetate using it
DK1870417T3 (en) Peptide ligation methods
BRPI0608180A2 (en) nucleic acids that bind to ghrelin
WO2004048526A3 (en) MODULATION OF HIF1α AND HIF2α EXPRESSION
DE69431669T2 (en) ENZYMATIC NUCLEIC ACID THAT CONTAINS NON-NUCLEOTIDS
DE60232653D1 (en) PHARMACEUTICALALLY EFFECTIVE URIDINE TESTER
DE60310944D1 (en) OTHER NEW FORMS OF INTERFERING RNS MOLECULES
EP2284267A3 (en) Modulation of diacylglycerol acyltransferase 2 expression
BRPI0520369A2 (en) organic catalyst with enhanced enzyme compatibility
BR0214035A (en) Compound
EP1633302A4 (en) Modulation of apolipoprotein (a) expression
AR024944A1 (en) AMIDAS OF CARBOXILIC ACIDS, MEDICATIONS CONTAINING THESE COMPOUNDS, THEIR USE AND THEIR PREPARATION
ATE417127T1 (en) NUKELIC ACID SEQUENCE DETERMINATION USING ELECTRONIC DETECTION
ATE232873T1 (en) PHOSPHONIC ACID DERIVATIVES AS PTP-1B INHIBITORS
BR9508308A (en) Benzoyl derivatives and their synthesis
WO2004055162A3 (en) Modulation of endothelial lipase expression
DE602005020185D1 (en) PROCESS FOR PREPARATION OF 17-HYDROXY-6 BETA, 7 BETA, 15 BETA, 16 BETA-BISMETHYLENE-17ALPHA-PREGN-4HEN PRODUCTS FOR THIS PROCESS
DK1594885T3 (en) Drug for growth inhibition of tumors
SE9804212D0 (en) Compounds
NO20014241D0 (en) C16-unsaturated FP-selective prostaglandin analogs
TR200003065T2 (en) Pyrrolidines as inhibitors of neuraminidases.
WO2005021727A3 (en) Isoform-specific targeting of splice variants
CY1111004T1 (en) USEFUL COMPOSITIONS FOR REGULATING PARKIN GENE ACTION

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees